Lycored makes a play for European Beauty From Within market

On the back of a successful US launch, Lycored will release its nutraceutical ingredient in Europe as it predicts growth opportunities for the Beauty from Within segment.

The ingredient contains a combination of nutrients including rosemary-derived carnosic acid as well as lycopene, phytoene and phytofluene extracted from tomatoes. 

Lycored showcased its Beauty from Within range as well as Cardi-O-Mato, an ingredient targetting cardiovascular health at Vitafoods this week.

Dr Tal Offer, product manager for dietary supplement technologies, said that the category was - and would continue to be - a significant market in terms of consumer interest.

No health claims for Europe

Although Lycored makes a number of health claims for Lyc-o-Derm that are authorised for the American market – protecting against photo-ageing, increasing skin smoothness and preventing DNA damage caused by sun exposure - the company said it would not be submitting any health claim petitions to EFSA.  

Industry insiders had suggested that it was this lack of authorised health claims that led to the demise of Innéov, Nestlé and L’Oréal’s joint venture in the Beauty From Within category that performed poorly and was shut down last year.

But Offer told NutraIngredients that European consumers would not be deterred by Lyc-o-Derm’s lack of claims.  

“The motivation behind our clinical efforts isn’t to register a claim, but to provide the brands and the end-consumer with nutrition technologies that are proven to be effective and safe.

“… We believe the proof of efficacy isn’t related to a regulatory approval but to the results of well-controlled clinical trials.”

She said that building new markets took time - especially with products such as ingredients for supplements that do not give an instant gratification as found in other sectors.

"Lycored are not directly in that space as we are offering the product primarily on a B2B level, however, The Beauty from Within is, and will continue to be, a significant market based on consumer interest. We have recently completed additional clinical trials which further supports our formulations."